Charles Schwab’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

Charles Schwab’s Portfolio THRX Stock Details THRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-56,203	Closed	-$228K	–	3553
2023 Q4	$228K	Hold	56,203	–	–	﹤0.01%	3261
2023 Q3	$151K	Hold	56,203	–	–	﹤0.01%	3325
2023 Q2	$524K	Buy	56,203 +11,092	+25%	+$109K	﹤0.01%	3035
2023 Q1	$401K	Buy	45,111 +1,784	+4%	+$17.5K	﹤0.01%	3023
2022 Q4	$216K	Hold	43,327	–	–	﹤0.01%	3173
2022 Q3	$252K	Hold	43,327	–	–	﹤0.01%	3133
2022 Q2	$240K	Buy	43,327 +11,098	+34%	+$91.7K	﹤0.01%	3220
2022 Q1	$372K	Buy	32,229 +1,285	+4%	+$13.7K	﹤0.01%	3165
2021 Q4	$393K	Buy	+30,944	New	+$467K	﹤0.01%	3225

Charles Schwab's THRX Position: Q1 2024 in Review

Charles Schwab sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q1 2024, closing a stake of 56,203 shares — an estimated $228K sold.

Charles Schwab first reported a position in THRX in Q4 2021 and held it in 9 quarters. The position peaked at $524K in Q2 2023. 1 fund tracked by Wall St. Rank holds THRX as of Q1 2024.

Charles Schwab reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Charles Schwab sold 56,203 Theseus Pharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $228K.
Charles Schwab first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 9 quarters.
Charles Schwab's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $524K in Q2 2023.
1 fund tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Charles Schwab's 13F filing for Q1 2024, filed 9 May 2024.